Real-world study to monitor Wegovy® patient body composition and cardiovascular health via connected devices
Background
Obesity is a chronic disease with numerous comorbidities, driving the need for effective treatments. While GLP-1 analogs like semaglutide have shown promising advances, there's a gap in understanding the real-world kinetics and interindividual variability of changes in body weight, composition, and cardiovascular health among patients receiving these therapies. This study addresses the need for comprehensive, real-world assessment of patients with severe obesity treated with Wegovy®.
Study Design
This prospective, non-interventional, single-arm study will enroll 80 estimated patients with severe obesity treated with Wegovy® 2.4 mg weekly subcutaneous injection. Participants will use a Withings Body Comp Pro connected scale to collect real-world data over 104 weeks. Primary endpoints include monitoring body weight, body composition (fat, muscle, bone mass), cardiovascular health (pulse wave velocity, arterial stiffness, vascular age, standing heart rate), and nervous health (electrochemical skin conductance).
Why It Matters
Understanding the real-world kinetics and variability of Wegovy®'s effects on body composition and cardiovascular health is crucial for optimizing patient care. This study will provide valuable insights into how patients respond to semaglutide beyond clinical trial settings, potentially informing more personalized treatment strategies. Real-time monitoring via connected devices could enable clinicians to track patient progress more effectively, identify individual response patterns, and potentially intervene earlier to manage comorbidities or adjust treatment plans, moving towards a more data-driven approach to obesity management.
semaglutide
wegovy
obesity
real-world-data
connected-devices
body-composition